Eris Lifesciences reported solid growth for FY2026, with consolidated revenue rising 8.1% to ₹3,129 crore and EBITDA growing 10.1% to ₹1,120 crore. The company saw significant expansion in its domestic branded formulations and a strong market entry for its new Semaglutide brand, Sundae. Despite some supply chain headwinds in international business, Eris improved its overall margins and significantly reduced its net debt, strengthening its position in the diabesity and insulin segments.
Financial Performance Highlights
For the fiscal year ending March 31, 2026, Eris Lifesciences delivered resilient performance. The consolidated revenue reached ₹3,129 crore, marking an 8.1% year-on-year growth. Consolidated EBITDA for the year stood at ₹1,120 crore, a 10.1% increase over the previous year, with EBITDA margins expanding to 36%. The Profit After Tax (PAT) from operations reached ₹498 crore for FY2026, representing a 34% year-on-year growth.
Domestic Branded Formulations (DBF)
The DBF segment remained the cornerstone of growth, contributing ₹2,778 crore to revenue, an 11% increase year-on-year. The segment’s EBITDA grew by 12% to ₹1,026 crore, with margins reaching 37%. The insulin segment was a key driver, with Eris’s insulin market share rising from 12% to 16% during the year, significantly outpacing the overall market growth.
Launch of Sundae (Semaglutide)
The company achieved a robust start for Sundae, its Semaglutide brand. Within the first month of launch, Eris captured a 22% share of prescriptions and reached the #1 rank in injectables by sale volume. This performance validates the company’s focus on its diabesity platform and establishes a strong footing in the high-growth GLP-1 segment.
International Business and Operational Outlook
The international business reported annual revenue of ₹348 crore, showing a 7% growth despite supply chain disruptions that affected Q4 shipments. While the company encountered temporary hurdles with EU-GMP inspection observations, these are deemed procedural with minimal impact on existing operations. Looking ahead to FY2027, Eris has provided revenue growth guidance of 18-20% for its existing business.
Balance Sheet Strength
Eris continues to strengthen its financial health, reporting a closing net debt of ₹2,255 crore. This reflects a significant improvement, bringing leverage down to 2x of EBITDA, compared to 4x in FY2024. The company remains committed to investing in high-potential areas like biologics and sterile injectables to drive long-term value.
Source: BSE
